Multi-disciplinary team of the treatment of heart transplantation for Danon disease

Lin Hengqiang; Liu Sheng; Huang Jie; Du Juan; Chen Lei; Wang Hongyue

doi:10.3969/j.issn.1674-7445.2021.01.010

Volume 12 Issue 1

Jan. 2021

Turn off MathJax

Article Contents

Article Navigation > ORGAN TRANSPLANTATION > 2021 > 12(1): 64-69

Lin Hengqiang, Liu Sheng, Huang Jie, et al. Multi-disciplinary team of the treatment of heart transplantation for Danon disease[J]. ORGAN TRANSPLANTATION, 2021, 12(1): 64-69. doi: 10.3969/j.issn.1674-7445.2021.01.010

Citation:

PDF( 1279 KB)

Multi-disciplinary team of the treatment of heart transplantation for Danon disease

doi: 10.3969/j.issn.1674-7445.2021.01.010

Department of Adult Cardiac Surgery, Fuwai Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100037, China

More Information

Corresponding author: Liu Sheng, E-mail:fuwailiusheng@sina.com
Received Date: 2020-11-29
Available Online: 2021-01-19
Publish Date: 2021-01-19

Abstract

Abstract

Objective To improve the understanding of Danon disease and the efficacy of heart transplantation by multi-disciplinary team (MDT) pattern. Methods Prior to heart transplantation, MDT consultation was performed on one case of Danon disease, an extremely rare X-chromosome dominant genetic disease. The content of consultation included surgical indication, preoperative preparation and postoperative precaution, as well as the role of MDT in the treatment of Danon disease was summarized. Results Preoperative echocardiography showed that the patient presented withdilated-phase of hypertrophic cardiomyopathy complicated with heart failure, which was considered as Danon disease with end-stage heart failure. After MDT consultation, the patient received the preoperative treatment including anti-heart failure, reduction of pulmonary artery pressure, intra-aortic balloon pump (IABP) assistance, liver protection, strengthening nutritional support, etc. The patient underwent orthotopic heart transplantation after a suitable donor was matched. The patient developed muscle weakness in the limbs 5 days after operation, which was gradually mitigated after reducing the dose of glucocorticoid. At postoperative 48 days, the patient was discharged in good condition and continually treated with triple immunosuppressive regimen after discharge. Reexamination at postoperative 6 months revealed that the patient was in good health without any abnormality in electrocardiogram and echocardiography images. Conclusions Danon disease is extremely rare and MDT pattern may enhance the efficacy and safety of treatment by heart transplantation.

FullText(HTML)

References(34)

References

[1]	DANON MJ, OH SJ, DIMAURO S, et al. Lysosomal glycogen storage disease with normal acid maltase[J]. Neurology, 1981, 31(1):51-57. DOI: 10.1212/wnl.31.1.51.
[2]	TANAKA Y, GUHDE G, SUTER A, et al. Accumulation of autophagic vacuoles and cardiomyopathy in LAMP-2-deficient mice[J]. Nature, 2000, 406(6798):902-906. DOI: 10.1038/35022595.
[3]	KOVACS WJ, SHACKELFORD JE, TAPE KN, et al. Disturbed cholesterol homeostasis in a peroxisome-deficient PEX2 knockout mouse model[J]. Mol Cell Biol, 2004, 24(1):1-13. DOI: 10.1128/mcb.24.1.1-13.2004.
[4]	BEERTSEN W, WILLENBORG M, EVERTS V, et al. Impaired phagosomal maturation in neutrophils leads to periodontitis in lysosomal-associated membrane protein-2 knockout mice[J]. J Immunol, 2008, 180(1):475-482. DOI: 10.4049/jimmunol.180.1.475.
[5]	KHANDIA R, DADAR M, MUNJAL A, et al. A comprehensive review of autophagy and its various roles in infectious, non-infectious, and lifestyle diseases: current knowledge and prospects for disease prevention, novel drug design, and therapy[J]. Cells, 2019, 8(7):674. DOI: 10.3390/cells8070674.
[6]	NASCIMBENI AC, FANIN M, ANGELINI C, et al. Autophagy dysregulation in Danon disease[J]. Cell Death Dis, 2017, 8(1):e2565. DOI: 10.1038/cddis.2016.475.
[7]	ROWLAND TJ, SWEET ME, MESTRONI L, et al. Danon disease - dysregulation of autophagy in a multisystem disorder with cardiomyopathy[J]. J Cell Sci, 2016, 129(11):2135-2143. DOI: 10.1242/jcs.184770.
[8]	NISHINO I, FU J, TANJI K, et al. Primary LAMP-2 deficiency causes X-linked vacuolar cardiomyopathy and myopathy (Danon disease)[J]. Nature, 2000, 406(6798): 906-910. DOI: 10.1038/35022604.
[9]	CHARRON P, VILLARD E, SÉBILLON P, et al. Danon's disease as a cause of hypertrophic cardiomyopathy: a systematic survey[J]. Heart, 2004, 90(8):842-846. DOI: 10.1136/hrt.2003.029504.
[10]	SUGIE K, YAMAMOTO A, MURAYAMA K, et al. Clinicopathological features of genetically confirmed Danon disease[J]. Neurology, 2002, 58(12):1773-1778. DOI: 10.1212/wnl.58.12.1773.
[11]	GUO S, ZHOU L, WANG R, et al. Danon disease: two patients with atrial fibrillation in a single family and review of the literature[J]. Exp Ther Med, 2019, 18(3):1527-1532. DOI: 10.3892/etm.2019.7777.
[12]	ROOS JCP, DANIELS MJ, MORRIS E, et al. Heterogeneity in a large pedigree with Danon disease: implications for pathogenesis and management[J]. Mol Genet Metab, 2018, 123(2):177-183. DOI: 10.1016/j.ymgme.2017.06.008.
[13]	CENACCHI G, PAPA V, PEGORARO V, et al. Review: Danon disease: review of natural history and recent advances[J]. Neuropathol Appl Neurobiol, 2020, 46(4):303-322. DOI: 10.1111/nan.12587.
[14]	KONRAD T, SONNENSCHEIN S, SCHMIDT FP, et al. Cardiac arrhythmias in patients with Danon disease[J]. Europace, 2017, 19(7):1204-1210. DOI: 10.1093/europace/ euw215.
[15]	CHENG Z, FANG Q. Danon disease: focusing on heart[J]. J Hum Genet, 2012, 57(7):407-410. DOI: 10.1038/jhg.2012.72.
[16]	HEDBERG OLDFORS C, MÁTHÉ G, THOMSON K, et al. Early onset cardiomyopathy in females with Danon disease[J]. Neuromuscul Disord, 2015, 25(6):493-501. DOI: 10.1016/j.nmd.2015.03.005.
[17]	BOUCEK D, JIRIKOWIC J, TAYLOR M. Natural history of Danon disease[J]. Genet Med, 2011, 13(6):563-568. DOI: 10.1097/GIM.0b013e31820ad795.
[18]	ECHANIZ-LAGUNA A, MOHR M, EPAILLY E, et al. Novel LAMP-2 gene mutation and successful treatment with heart transplantation in a large family with Danon disease[J]. Muscle Nerve, 2006, 33(3):393-397. DOI: 10.1002/mus.20471.
[19]	DU CZ, LI J, CAI Y, et al. Effect of multidisciplinary team treatment on outcomes of patients with gastrointestinal malignancy[J]. World J Gastroenterol, 2011, 17(15):2013-2018. DOI: 10.3748/wjg.v17.i15.2013.
[20]	FRIEDLAND PL, BOZIC B, DEWAR J, et al. Impact of multidisciplinary team management in head and neck cancer patients[J]. Br J Cancer, 2011, 104(8):1246-1248. DOI: 10.1038/bjc.2011.92.
[21]	SAMAD F, JAIN R, JAN MF, et al. Malignant cardiac phenotypic expression of Danon disease (LAMP2 cardiomyopathy)[J]. Int J Cardiol, 2017, 245:201-206. DOI: 10.1016/j.ijcard.2017.06.031.
[22]	ENDO Y, FURUTA A, NISHINO I. Danon disease: a phenotypic expression of LAMP-2 deficiency[J]. Acta Neuropathol, 2015, 129(3):391-398. DOI: 10.1007/s00401- 015-1385-4.
[23]	D'SOUZA RS, LEVANDOWSKI C, SLAVOV D, et al. Danon disease: clinical features, evaluation, and management[J]. Circ Heart Fail, 2014, 7(5):843-849. DOI: 10.1161/CIRCHEARTFAILURE.114.001105.
[24]	HENSLEY N, DIETRICH J, NYHAN D, et al. Hypertrophic cardiomyopathy: a review[J]. Anesth Analg, 2015, 120(3): 554-569. DOI: 10.1213/ANE.0000000000000538.
[25]	CHAVES-MARKMAN Â, MARKMAN M, SANTOS-VELOSO MAO, et al. Familial hypertrophic cardiomyopathy: late potentials and other prognostic markers[J]. Cureus, 2020, 12(1):e6530. DOI: 10.7759/cureus.6530.
[26]	TOBITA T, NOMURA S, FUJITA T, et al. Genetic basis of cardiomyopathy and the genotypes involved in prognosis and left ventricular reverse remodeling[J]. Sci Rep, 2018, 8(1):1998. DOI: 10.1038/s41598-018-20114-9.
[27]	KOHLER L, PUERTOLLANO R, RABEN N. Pompe disease: from basic science to therapy[J]. Neurotherapeutics, 2018, 15(4):928-942. DOI: 10.1007/s13311-018-0655-y.
[28]	COLELLA P, MINGOZZI F. Gene therapy for Pompe disease: the time is now[J]. Hum Gene Ther, 2019, 30(10):1245-1262. DOI: 10.1089/hum.2019.109.
[29]	YAMAMOTO A, MORISAWA Y, VERLOES A, et al. Infantile autophagic vacuolar myopathy is distinct from Danon disease[J]. Neurology, 2001, 57(5):903-905. DOI: 10.1212/wnl.57.5.903.
[30]	MUNTEANU I, KALIMO H, SARASTE A, et al. Cardiac autophagic vacuolation in severe X-linked myopathy with excessive autophagy[J]. Neuromuscul Disord, 2017, 27(2):185-187. DOI: 10.1016/j.nmd.2016.10.007.
[31]	STEVENS-LAPSLEY JE, KRAMER LR, BALTER JE, et al. Functional performance and muscle strength phenotypes in men and women with Danon disease[J]. Muscle Nerve, 2010, 42(6):908-914. DOI: 10.1002/mus.21811.
[32]	BRAMBATTI M, CASPI O, MAOLO A, et al. Danon disease: gender differences in presentation and outcomes[J]. Int J Cardiol, 2019, 286:92-98. DOI: 10.1016/j.ijcard.2019.01.020.
[33]	VAN DER STARRE P, DEUSE T, PRITTS C, et al. Late profound muscle weakness following heart transplantation due to Danon disease[J]. Muscle Nerve, 2013, 47(1):135-137. DOI: 10.1002/mus.23517.
[34]	OREN D, CHAU P, MANNING M, et al. Heart transplantation in two adolescents with Danon disease[J]. Pediatr Transplant, 2019, 23(2):e13335. DOI: 10.1111/petr.13335.

Relative Articles

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(2)

Get Citation

PDF

XML

Article Metrics

Article views (223) PDF downloads(25)

Multi-disciplinary team of the treatment of heart transplantation for Danon disease

doi: 10.3969/j.issn.1674-7445.2021.01.010

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Multi-disciplinary team of the treatment of heart transplantation for Danon disease

doi: 10.3969/j.issn.1674-7445.2021.01.010

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Export File

Citation

Format

Content